Smiths Share Discussion Threads

[philanderer] 28/9/2021 16:04

In here today :-)

Luck to all.

[ltinvestor] 08/9/2021 08:31

Great announcement totally overlooked….

[essentialinvestor] 23/8/2021 23:04

Taken a very small amount.

SMIN tends to be hit hard on any equity volatility,
so mindful of that going in to Q3.

[kennewil] 03/8/2021 16:21

Sale of medical arm not going down too well.

[philanderer] 12/7/2021 10:46

GOLDMAN SACHS CUTS SMITHS GROUP PRICE TARGET TO 1,880 (1,920) PENCE - 'BUY'

[w1lbur01] 10/7/2021 22:39

Smiths Group faces break-up as private equity buyer swoops https://mol.im/a/9775581

[pugugly] 26/5/2021 09:09

Marker re Lex today Now up 1% at 1557p

[philanderer] 25/5/2021 14:54

Smiths Group: Citigroup reiterates buy with a target price of 1,900p.

[thewheeliedealer] 26/12/2020 23:24

Hi all,

My mate Peter @Conkers3 and myself did a ‘Twin Petes Investing’ Podcast a few days before Xmas and part of our discussion includes SMIN which C3 holds. We also chatted about loads of other Stocks and Ideas for research. We discussed the outlook for Markets and the most likely roadmap for the next couple of months, and as usual a fair bit of educational stuff with regards to Investing.

Anyway, if you use Youtube, Apple, Audioboom, Overcast or Spotify you can find it under the 'Conkers Corner' Channel (you want Podcast TPI 38) and you can find it on Soundcloud at the link below.

I hope you enjoy it and find it useful, we try to keep them light and they are totally unscripted, not like all the stuffy financial fodder you are probably more used to !!

Season’s Greetings !! WD
@wheeliedealer

[jonnybig] 16/11/2020 13:39

Nice update, glad I got this in the march crash. Still holding, not jumping yet.

[maxplus2] 20/10/2020 11:49

Rerating going

[pharmaboy3] 09/7/2020 14:50

Bought 3 months ago based purely on ventilator manufacturing as a hedge against Covid. Then realise their full medical and security range.Excellent British company.Up 60 % in 3 months

[broadwood] 20/9/2019 07:51

tWire.com - Industrial and medical products supplier Smiths booked a 19% fall in first-half profit and said a spin-off of its medical division was on track for the first half of 2020.

Net profit, including one-off profits and losses from discontinued operations, fell to £227m, down from £279m on-year.

Pre-tax profit from continuing operations rose 19% to £142m, as revenue from continuing operations rose 7% to £2.50bn.

The company's operating margin rose 40 basis points to 17.1%.

Smiths declared a full-year dividend of 45.90p per share, up 3% on-year.

Its medical division returned to growth in the second half with revenue up 2%, delivering flat revenue for the year overall at £874m, in line with expectations.

Headline operating profit in the division, however, fell 6% on an underying basis.

Smiths said that it expected to notch further overall growth in the current financial year, weighted towards the first half that would result in a more even balance in overall performance between the first and second halves.

'We continue to build sustainable growth, paving the way to outperform our markets,' chief executive Andy Reynolds said.

'Importantly, this growth was coupled with enhanced margins, we have now delivered a 300 basis points margin improvement since 2016.'

'In addition, we continued to optimise our portfolio, with two acquisitions completed in the year.'

[broadwood] 31/8/2019 15:48

Bidders circling - Daily Mail.

[paulisi] 29/8/2019 12:55

UK airports likely to purchase new scanners as per news stories.Should be beneficial for Smith's Group.

[philanderer] 29/8/2019 09:53

GOLDMAN SACHS RAISES SMITHS GROUP TO 'BUY' ('NEUTRAL') - TARGET 1850 (1650) PENCE

[nigelbarker] 29/8/2019 08:35

rather interesting

[rambo1976] 25/3/2019 08:29

double cap viewable options

[rimau1] 22/3/2019 08:16

All seems in line, looking forward to unlocking significant value from the demerger, conglomerates rarely work for shareholders. No brainer long term investment alongside PRU and WTB where demerger value will always flow through with patience. I am a happy holder and will add on any dips.

[broadwood] 22/3/2019 07:32

dustrial technology company Smiths Group booked a 13% fall in first-half profit as it revealed plans to spin off its under-performing medical business into a separately listed company.

Pre-tax profit for the year through January declined to £174m, even as revenue rose 2% to £1.57bn.

On an underlying basis, pre-tax profit fell by a more modest 1% to £216m.

The company's operating margin fell 140 basis points to 13.5%.

Smiths Group declared an interim dividend of 14.1p per share, up 2.2% on-year.

The company said it expected to complete the demerger process during the first half of calendar 2020, conditional on shareholder approval.

'Smiths delivered another good performance in the first half with sustainable growth driven by John Crane, Flex-Tek and Smiths Interconnect,' chief executive Andy Reynolds Smith said.

'The strong results from these divisions were partly offset by the anticipated decline in Smiths Medical and the timing of deliveries in Smiths Detection, with both on track to deliver growth in the second half.'

'Today we have announced our plans for the separation of Smiths Medical to create two stronger companies each focusing on accelerating the execution of their plans and maximising the opportunities in their respective markets.

'We reaffirm our outlook for 2019.'

'We expect to continue to deliver sustainable underlying revenue growth of at least 2%, underpinned by current trading of our four industrial technology divisions and by the increasing contribution from new product launches in Smiths Medical.'

[broadwood] 08/8/2018 07:47

Smiths Group, the FTSE-100 in‎dustrial conglomerate, is close to calling off talks with a rival about a £7bn merger that would have created a transatlantic healthcare giant.
Sky News has learnt that Smiths is leaning towards a decision to halt negotiations with Nasdaq-listed ICU Medical about a tie-up more than two months after they got underway.

A final decision has yet to be made by Smiths' chief executive, Andy Reynolds Smith, and a person close to the British company insisted on Tuesday night that any change in its position would be announced immediately to the London Stock Exchange.
Banking sources said that news of the talks between Smiths and ICU, which were confirmed after Sky News revealed them in May, had prompted Baxter International, another US healthcare company, to express an interest in buying Smiths Medical outright.
It was unclear whether any live talks were still taking place between Smiths and Baxter or any other potential suitors.
News of the discussions was welcomed by Smiths investors in May amid hopes that the company was close to unlocking part of the value bound up in its conglomerate structure.
Since then, both Smiths and ICU are said to have tabled a string of proposals about how a combination could work, with varying degrees of governance and management control being held by the two parties.
ICU, which makes devices used in infusion therapy and oncology, is thought to have been keen on a formal merger of the businesses rather than a more straightforward joint venture.
The Nasdaq-listed ICU has a market value of $6bn‎ (£4.6bn), while Smiths Medical was likely to have been valued at more than £2.5bn (£1.9bn) in a transaction.
The US-based company has a long track record of takeovers including the $900m purchase completed last year of Pfizer's Hospira Infusion Systems arm.
Smiths Medical, which also supplies advanced devices to healthcare markets around the world, accounts for just under 30% of the group's revenues, making it the company's largest unit on that basis.
Its performance has been rocky in recent years, with revenue in the half-year to January down 5% to £451m.
Last month, Smiths Group shares tumbled after the company said that changes to European Union rules on medical devices would hurt sales from 2020.
The company said this year that it was making "significant progress on its return to growth" in the medical‎ arena but cautioned that higher research and development costs were having an impact on short-term profitability.
Smiths also operates in areas such as security detection, making much of the body-scanning equipment used at airports around the world.
In total, it has five main divisions‎, which also include John Crane, a provider of engineering solutions for energy and other process industries.
The company's structure has long been a source of consternation for some investors and analysts, although talk of a takeover or break-up has never resulted in significant corporate activity.
In recent months there has been growing talk among City investors that Smiths is likely to attract the attention of an activist investor keen on pressing more aggressively for a break-up, although its shares have generally performed strongly in recent months and are up modestly over the last year.
Such activism has become increasingly common in the UK‎, with companies including FirstGroup, the transport operator, drug-maker Shire and Costa Coffee-owner Whitbread all the subject of current campaigns.
Mr Reynolds Smith, who joined the company in 2015 from GKN, the engineering firm which has just been bought by Melrose Industries, is under pressure to demonstrate that its existing structure continues to deliver benefits to shareholders.

[sandlab] 28/5/2018 11:17

Article in The Times today - "early stage", "joint venture" etc

Smiths Group in talks over healthcare ‘merger’ with US rival ICU Medical

//www.thetimes.co.uk/edition/business/smiths-group-in-talks-over-healthcare-merger-with-us-rival-icu-medical-zrznxsvq3

[broadwood] 02/5/2018 16:19

Getting a nice little run going.